Pascal Zufferey1, Claudia Rebell2, Charles Benaim2, Hans Ruedi Ziswiler3, Alexandre Dumusc2, Alexander So2. 1. Department of rheumatology, Lausanne university hospital, 4, avenue Pierre-Decker, 1011 Lausanne, Switzerland. Electronic address: Pascal.zufferey@chuv.ch. 2. Department of rheumatology, Lausanne university hospital, 4, avenue Pierre-Decker, 1011 Lausanne, Switzerland. 3. OsteoRheuma, Bern, Switzerland.
Abstract
INTRODUCTION: Ultrasound (US) subclinical synovitis in prerheumatoid arthritis (RA) patients has been demonstrated in anticitrullinated antibodies (ACPA) positive patients to be predictive for future development of RA. The aim of the study was to assess the value of the US as a predictive factor for the future development of RA in patients with polyarthralgia without ACPA. METHOD: Eighty consecutive ACPA-patients with polyarthralgia without clinical synovitis or ACPA before the US examination were included. To detect significant US synovitis, we applied the criteria of a US score (SONAR) validated among RA patients and controls. The diagnosis of RA was based on the ACR/EULAR criteria. RESULTS: Significant US synovitis were present at baseline in 20 (25%) of the patients. The mean (SD) follow-up time was 18 (7) months in both groups. Seven (9%) patients developed a clear RA and 2 another inflammatory arthritis. US synovitis at baseline was significantly associated with evolution to RA: 5/20 (25%) versus 2/60 (3%) (P<0.05). The free time to RA was significantly shorter when US synovitis were present (P<0.01). Moreover, after multivariate analysis, US appeared to be the only independent predictor of an evolution to RA (OR: 7.4). Results remained similar after including all patients developing another inflammatory arthritis. CONCLUSIONS: Our study suggests that US can be used as a predictor for the evolution to RA or other inflammatory arthritis in patients presenting polyarthralgia without ACPA.
INTRODUCTION: Ultrasound (US) subclinical synovitis in prerheumatoid arthritis (RA) patients has been demonstrated in anticitrullinated antibodies (ACPA) positive patients to be predictive for future development of RA. The aim of the study was to assess the value of the US as a predictive factor for the future development of RA in patients with polyarthralgia without ACPA. METHOD: Eighty consecutive ACPA-patients with polyarthralgia without clinical synovitis or ACPA before the US examination were included. To detect significant US synovitis, we applied the criteria of a US score (SONAR) validated among RApatients and controls. The diagnosis of RA was based on the ACR/EULAR criteria. RESULTS: Significant US synovitis were present at baseline in 20 (25%) of the patients. The mean (SD) follow-up time was 18 (7) months in both groups. Seven (9%) patients developed a clear RA and 2 another inflammatory arthritis. US synovitis at baseline was significantly associated with evolution to RA: 5/20 (25%) versus 2/60 (3%) (P<0.05). The free time to RA was significantly shorter when US synovitis were present (P<0.01). Moreover, after multivariate analysis, US appeared to be the only independent predictor of an evolution to RA (OR: 7.4). Results remained similar after including all patients developing another inflammatory arthritis. CONCLUSIONS: Our study suggests that US can be used as a predictor for the evolution to RA or other inflammatory arthritis in patients presenting polyarthralgia without ACPA.
Authors: Garifallia Sakellariou; Carlo Alberto Scirè; Antonella Adinolfi; Alberto Batticciotto; Alessandra Bortoluzzi; Andrea Delle Sedie; Orazio De Lucia; Christian Dejaco; Oscar Massimiliano Epis; Emilio Filippucci; Luca Idolazzi; Andrea Picchianti Diamanti; Alen Zabotti; Annamaria Iagnocco; Georgios Filippou Journal: Front Med (Lausanne) Date: 2020-05-07
Authors: Marian H van Beers-Tas; Annelies B Blanken; Mark M J Nielen; Franktien Turkstra; Conny J van der Laken; Marlies Meursinge Reynders; Dirkjan van Schaardenburg Journal: Arthritis Res Ther Date: 2018-12-19 Impact factor: 5.156
Authors: Sarah Ohrndorf; Aleid C Boer; Debbie M Boeters; Robin M Ten Brinck; Gerd-R Burmester; Marion C Kortekaas; Annette H M van der Helm-van Mil Journal: Arthritis Res Ther Date: 2019-02-14 Impact factor: 5.156
Authors: Laure Brulhart; Deshiré Alpízar-Rodríguez; Michael S Nissen; Pascal Zufferey; Ileana Ciubotariu; Gregory Fleury; Ilias Lazarou; Cem Gabay; Axel Finckh Journal: RMD Open Date: 2019-08-23
Authors: Xanthe M E Matthijssen; Fenne Wouters; Debbie M Boeters; Aleid C Boer; Yousra J Dakkak; Ellis Niemantsverdriet; Annette H M van der Helm-van Mil Journal: Arthritis Res Ther Date: 2019-11-27 Impact factor: 5.156
Authors: Kulveer Mankia; Heidi Siddle; Andrea Di Matteo; Deshiré Alpízar-Rodríguez; Joel Kerry; Andreas Kerschbaumer; Daniel Aletaha; Paul Emery Journal: RMD Open Date: 2021-09
Authors: Ruediger Mueller; Mathias Grunke; Jörg Wendler; Florian Schuch; Karina Hofmann-Preiss; Ina Boettger; Rüdiger Jakobs; Hendrik Schulze-Koops; Johannes von Kempis Journal: Ultrasound Int Open Date: 2018-07-11
Authors: Rosaline van den Berg; Sarah Ohrndorf; Marion C Kortekaas; Annette H M van der Helm-van Mil Journal: Arthritis Res Ther Date: 2018-10-11 Impact factor: 5.156